Yamamoto Y, Suzuki S, Hamabe L, Aytemiz D, Huai-Che H, Kim S, Yoshiyuki R, Fukayama T, Fukushima R, Tanaka R
Department of Veterinary Surgery, Faculty of Veterinary Medicine, Tokyo University of Agriculture and Technology, Tokyo, Japan.
J Vet Intern Med. 2013 Nov-Dec;27(6):1421-6. doi: 10.1111/jvim.12184. Epub 2013 Sep 6.
The effects of isosorbide dinitrate (ISDN) have not been sufficiently investigated in conscious dogs with mitral valve regurgitation (MR).
The objective was to investigate the effects of a sustained-release form of ISDN (sr-ISDN) on hemodynamics and the autonomic nervous system in dogs with MR.
Six healthy Beagles weighing 11.2 ± 2.2 kg (2 years of age; 2 males and 4 females) were used.
Experimental, crossover, and interventional study. Dogs with experimentally induced MR were administered placebo, 2, 5, and 10 mg/kg sr-ISDN PO on separate days with a 7-day washout period between randomized dosings. Left atrial pressure (LAP) had been recorded continuously from 30 minutes before administration of sr-ISDN to 12 hours after administration.
LAP was significantly decreased after administration in the 5 and 10 mg/kg groups. Significant decrease was observed at 3 and 4 hours after administration in the 5 mg/kg group. In the 10 mg/kg group, significant decrease was observed at 2, 3, 4, 5, 6, 7, 10, and 11 hours after administration. The lowest value was observed at 4 hours after administration in the 5 and 10 mg/kg groups (20.9 ± 4.2 to 15.9 ± 3.9 mmHg, P < .01, and 21.3 ± 4.0 to 13.6 ± 4.2 mmHg, P < .001).
Sustained-release form of ISDN showed significant decrease of LAP in the 5 mg/kg and 10 mg/kg groups, and duration of effect was dose related.
在清醒的二尖瓣反流(MR)犬中,硝酸异山梨酯(ISDN)的作用尚未得到充分研究。
研究缓释型ISDN(sr-ISDN)对MR犬血流动力学和自主神经系统的影响。
使用6只健康的比格犬,体重11.2±2.2千克(2岁;2只雄性和4只雌性)。
实验性、交叉性和干预性研究。对实验诱导的MR犬在不同日期分别给予安慰剂、2、5和10毫克/千克的sr-ISDN口服,随机给药之间有7天的洗脱期。从给予sr-ISDN前30分钟至给药后12小时连续记录左心房压力(LAP)。
5毫克/千克和10毫克/千克组给药后LAP显著降低。5毫克/千克组在给药后3和4小时观察到显著降低。在10毫克/千克组,给药后2、3、4、5、6、7、10和11小时观察到显著降低。5毫克/千克和10毫克/千克组在给药后4小时观察到最低值(分别从20.9±4.2降至15.9±3.9毫米汞柱,P<.01;从21.3±4.0降至13.6±4.2毫米汞柱,P<.001)。
缓释型ISDN在5毫克/千克和10毫克/千克组中显示LAP显著降低,且作用持续时间与剂量相关。